Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZYMERGEN INC.

(ZY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymergen : Cuts 120 Jobs as Part of Restructuring Program to Align Group Costs With Delayed Revenue Ramp

09/23/2021 | 05:41pm EST


© MT Newswires 2021
All news about ZYMERGEN INC.
01/12HSBC Upgrades Zymergen to Hold From Reduce; Lowers Price Target to $6.50 From $8
MT
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
GL
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
AQ
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
GL
01/10Zymergen Launches Drug Discovery Unit
MT
01/09Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World's Large..
AQ
01/09Zymergen Announces New Drug Discovery Business Based Around Their Proprietary Synthetic..
CI
01/05Zymergen to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ZYMERGEN ALERT : Bragar Eagel & Squire, P.C. Is Investigating Zymergen Inc. on Behalf of L..
BU
2021INSIDER BUY : Zymergen
MT
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2021 17,0 M - -
Net income 2021 -372 M - -
Net cash 2021 309 M - -
P/E ratio 2021 -1,08x
Yield 2021 -
Capitalization 509 M 509 M -
EV / Sales 2021 11,8x
EV / Sales 2022 21,4x
Nbr of Employees 758
Free-Float 90,7%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 4,97 $
Average target price 8,80 $
Spread / Average Target 77,1%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Jed Dean Vice President-Operations & Engineering
Aaron Kimball Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.-25.71%499
BASF SE8.95%67 571
SHIN-ETSU CHEMICAL CO., LTD-8.96%66 122
DUPONT DE NEMOURS, INC.-5.00%39 806
ROYAL DSM N.V.-16.06%31 808
PIDILITE INDUSTRIES LIMITED5.13%17 599